The NO Pathway as a Target in Patients with Stable and Advanced Heart Failure: An Additional Arrow in Our Quiver!
Biomolecules · 06.10.2025 · 15 (10) · 1420
DOI: 10.3390/biom15101420 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 06.10.2025. Verfasst von Saverio D'Elia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Naples, Italy. Hauptthemen laut MEDLINE: Heart Failure, Nitric Oxide, Signal Transduction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The nitric oxide (NO) pathway is a fundamental regulator of vascular tone, myocardial function, and inflammation. In heart failure (HF), especially in advanced stages, dysregulation of NO–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) signaling contributes to endothelial dysfunction, increased vascular resistance, myocardial fibrosis, and impaired cardiac performance. Chronic inflammation further reduces NO bioavailability, exacerbating HF progression This review synthesizes current knowledge on the role of the NO pathway in HF pathophysiology, with a focus on stable and advanced HF. Special attention is given to patient subgroups with comorbidities such as chronic kidney disease, where modulation of NO signaling may be particularly beneficial. We also evaluate therapeutic strategies targeting NO bioavailability and sGC stimulation. Evidence shows that impaired NO signaling promotes systemic and pulmonary vasoconstriction, elevates ventricular afterload, and worsens cardiac remodeling. Pharmacological agents that restore NO levels or activate downstream effectors such as sGC improve vasodilation, reduce fibrosis, and enhance myocardial relaxation. These effects are especially relevant in advanced HF patients and those with renal impairment, who often exhibit limited responses to conventional therapies. The NO pathway represents a promising therapeutic target in both stable and advanced HF. Modulating this pathway could improve outcomes, particularly in complex populations with multiple comorbidities, highlighting the need for further clinical research and tailored treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Naples, Italy.
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Luigi Miraglia, 2, 80138 Naples, Italy.
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
- Department of Life Science, Health, and Health Professions, Link Campus University, 00165 Rome, Italy.
- Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy.
ORCID-Profile: Saverio D'Elia, Simona Covino, Francesco Natale, Paolo Golino, Giovanni Cimmino
Zitieren
APA
D'Elia, S., Gentile, C., Solimene, A., Franzese, R., Luisi, E., Caiazzo, A., Marotta, L., Covino, S., Natale, F., Loffredo, F. S., Golino, P., & Cimmino, G. (2025). The NO Pathway as a Target in Patients with Stable and Advanced Heart Failure: An Additional Arrow in Our Quiver!. Biomolecules, 15(10), 1420. https://doi.org/10.3390/biom15101420
Vancouver
D'Elia S, Gentile C, Solimene A, Franzese R, Luisi E, Caiazzo A, et al. The NO Pathway as a Target in Patients with Stable and Advanced Heart Failure: An Additional Arrow in Our Quiver!. Biomolecules. 2025;15(10):1420. doi:10.3390/biom15101420
BibTeX
@article{DElia2025,
author = {D'Elia, Saverio and Gentile, Carmine and Solimene, Achille and Franzese, Rosa and Luisi, Ettore and Caiazzo, Antonio and Marotta, Luigi and Covino, Simona and Natale, Francesco and Loffredo, Francesco S and Golino, Paolo and Cimmino, Giovanni},
title = {The NO Pathway as a Target in Patients with Stable and Advanced Heart Failure: An Additional Arrow in Our Quiver!},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {10},
pages = {1420},
doi = {10.3390/biom15101420}
}
EUVIMED